Addex Therapeutics Ltd.
Business
Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company focused on developing orally available small molecule allosteric modulators for neurological and respiratory conditions. Its main products and drug candidates include dipraglurant (an mGlu5 NAM), ADX71149 (an mGlu2 PAM) and a portfolio of GABAB PAM candidates for substance use disorder and chronic cough. The company organizes its activities into internally developed programs, partnered programs and a minority equity interest in the Neurosterix spin-out. It pursues worldwide development through collaborations, licensing, third‑party manufacturing and international clinical trial sites.
Summary from filing dated 2025-05-15
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-6.73M |
| Total assets | $6.36M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Addex Therapeutics Ltd.'s CIK number?
Addex Therapeutics Ltd.'s SEC CIK number is 0001574232 (1574232). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Addex Therapeutics Ltd.'s SEC filings?
All of Addex Therapeutics Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.